52North is dedicated to revolutionizing urgent oncology care by creating accessible and innovative diagnostic technologies that safeguard the health of patients undergoing chemotherapy worldwide. Their vision is to build a future where timely, affordable, and patient-centered digital solutions empower medical teams and patients alike to better manage cancer-related emergencies.
Driven by expert knowledge from Cambridge's academic and medical communities, 52North fuses clinical insight with advanced AI and integrated medical devices to transform how neutropenia and neutropenic sepsis are identified and mitigated at the point of care. This integrated approach aspires to reduce life-threatening chemotherapy complications on a global scale.
By harnessing technology to improve patient safety and equity across diverse socio-economic backgrounds, 52North is laying the foundation for a new paradigm of cancer care—one where innovative diagnostics enable confident remote management and improve outcomes for millions of vulnerable patients.
Our Review
We'll be honest — when we first heard about 52North, we weren't sure what to expect from another Cambridge-born healthtech startup. But after digging into their story, we're genuinely impressed by what this team has built in just six years.
Founded by four University of Cambridge postgrads in 2018, 52North isn't trying to solve every healthcare problem under the sun. Instead, they've laser-focused on one critical issue: keeping cancer patients safe during chemotherapy. That kind of clarity is refreshing in a space that's often cluttered with overly ambitious promises.
The Problem They're Actually Solving
Here's something that surprised us: neutropenia — a dangerous drop in white blood cells during chemo — affects up to 80% of cancer patients. Yet monitoring for this potentially life-threatening condition has remained frustratingly primitive. Patients often have to wait days for lab results, and by then, it might be too late.
52North's Neutrocheck flips this script entirely. It's a point-of-care device that gives healthcare teams real-time insights into a patient's risk levels, complete with AI-powered analysis. Think of it as an early warning system that actually works when you need it most.
What Really Caught Our Attention
Two things stand out about 52North's approach. First, they're not just building fancy tech for wealthy hospitals — they're explicitly designing for "all socio-economic groups." That's a mission statement you don't see often enough in medtech.
Second, their funding story tells us smart money believes in them. The €6 million Series A they closed in 2024 was co-led by KHP Ventures and Cedars-Sinai Intellectual Property Co. — marking the first joint investment between leading UK and US hospital venture funds. When two major healthcare systems put their money where their mouth is, that's worth paying attention to.
Why This Matters Now
Cancer care is expensive, complex, and often inequitable. 52North seems to understand that the best solutions aren't always the most complicated ones — sometimes, they're the ones that work reliably for everyone. Their recognition as "MedTech Company of the Year" in 2023 and selection as a MedTech Innovator finalist suggests the industry agrees.
With €9.5 million in total funding and partnerships with institutions like Imperial College London, 52North has the resources and credibility to scale. We're curious to see how quickly they can get Neutrocheck into the hands of oncology teams who need it most.
Clinical AI system to monitor chemotherapy patients for neutropenia risk
Point-of-care device and app for remote triaging
Integrated medical device with digital diagnostic tools
Affordable, patient-centered solutions for emergency cancer care management
Supports early detection and management of neutropenic sepsis
FAQs
52North
